I know what you mean. This stock should've been up near 1.80 before the "approval". Here we are, one day later and it's still available at bargain prices only a little above $1. (Thanks, SA experts.) I don't see how this one can miss. Hoping the conference call helps explain. Used to be if you weren't in before FDA, you missed the boat.